Which enzyme is responsible for the synthesis of precursor mRNA (pre-mRNA) in eukaryotes?

Transcription is the synthesis of RNA from a DNA template. In eukaryotes, it occurs in the nucleus and is significantly more complex than in prokaryotes. Three distinct nuclear RNA polymerases handle different gene classes, and extensive post-transcriptional processing converts primary transcripts (pre-mRNA, pre-rRNA, pre-tRNA) into functional RNA molecules. Additionally, RNA synthesis in eukaryotes is spatially separated from translation (which occurs in the cytoplasm), allowing time for RNA processing, quality control, and selective export of mature RNAs.

RNA Pol II is a large (~500 kDa) multisubunit enzyme consisting of 12 subunits (Rpb1-Rpb12 in yeast). The largest subunit (Rpb1) has a distinctive C-terminal domain (CTD) consisting of multiple repeats of the heptapeptide sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. The phosphorylation state of the CTD coordinates the transcription cycle: unphosphorylated CTD: associated with Mediator complex and Pol II is in the pre-initiation complex (PIC) at the promoter. Phosphorylation of Ser5 by TFIIH: triggers promoter clearance and initiation of RNA synthesis, also recruits 5' capping enzyme. Phosphorylation of Ser2 by P-TEFb: associated with productive elongation. The CTD acts as a scaffold, recruiting RNA processing factors (capping, splicing, polyadenylation machinery) that act co-transcriptionally on the nascent pre-mRNA.

After RNA Pol II initiates transcription, the nascent pre-mRNA undergoes three major co-transcriptional and post-transcriptional modifications before it can serve as an mRNA for translation. 5' capping: soon after transcription initiation, when the transcript is only 20-30 nucleotides long, a 7-methylguanosine (m7G) cap is added to the 5' end via an unusual 5'-5' triphosphate linkage. This cap protects the mRNA from 5' exonuclease degradation, is recognised by translation initiation factors for ribosome recruitment, and is required for nuclear export. 3' polyadenylation: a poly(A) signal sequence (AAUAAA) near the 3' end of the pre-mRNA is recognised by cleavage and polyadenylation specificity factor (CPSF), which cleaves the pre-mRNA 10-30 nucleotides downstream of the signal. Poly(A) polymerase then adds a poly(A) tail of 100-250 adenosine residues. The poly(A) tail increases mRNA stability and enhances translation efficiency. Splicing: non-coding intron sequences are precisely removed from the pre-mRNA by the spliceosome, a large ribonucleoprotein complex (RNP) containing five small nuclear RNAs (U1, U2, U4, U5, U6 snRNAs) and approximately 150 proteins. The spliceosome recognises consensus sequences at the 5' splice site, branch point, and 3' splice site, executing two sequential transesterification reactions to remove the intron as a lariat structure and join the flanking exons.

RNA Pol II cannot independently bind to gene promoters — it requires a series of general transcription factors (GTFs) that assemble at the core promoter (TATA box, around -25 to -30 bp upstream of transcription start site) to form the pre-initiation complex (PIC): TFIID (contains TATA-binding protein, TBP): recognises and binds TATA box. TFIIA and TFIIB: stabilise TBP-DNA interaction, help RNA Pol II recruitment. TFIIF: brings RNA Pol II to the promoter. TFIIE and TFIIH: TFIIH is a kinase that phosphorylates the CTD of RNA Pol II (activating it) and has helicase activity to melt the DNA at the transcription start site. This general transcription machinery provides basal (minimal) gene expression. Gene-specific regulation is accomplished by enhancers (bound by activator proteins that stimulate transcription) and silencers (bound by repressor proteins that inhibit transcription) — these elements can be thousands of base pairs away from the promoter and act on the Pol II PIC through DNA looping mediated by the Mediator complex. This regulatory system allows the precise spatial and temporal control of gene expression in different cell types and developmental stages.

The human genome contains approximately 20,000-25,000 protein-coding genes, yet the human proteome is estimated to contain hundreds of thousands of distinct proteins. This discrepancy is largely explained by alternative splicing of pre-mRNA. When a pre-mRNA is spliced, different subsets of exons can be selected for inclusion in the mature mRNA, generating multiple distinct mRNA isoforms from a single gene, each potentially encoding a different protein isoform with distinct structural, functional, or regulatory properties. It is estimated that approximately 95% of human multiexon genes undergo alternative splicing, making it an extraordinarily widespread regulatory mechanism. Types of alternative splicing: Exon skipping (most common): an internal exon is skipped, and its flanking introns are removed together. Alternative 5' splice sites: different positions used within the same intron at the 5' end. Alternative 3' splice sites: different positions at the 3' end. Intron retention: an intron remains in the mature mRNA. Mutually exclusive exons: one exon of a pair is always included. Alternative splicing is regulated by RNA-binding proteins that bind to exonic or intronic splicing enhancers or silencers, modulating the probability that the spliceosome will use particular splice sites. Dysregulation of alternative splicing occurs in many cancers and contributes to cancer-specific protein isoforms that promote tumour growth.

Several important human diseases result from defects in pre-mRNA processing. Spinal muscular atrophy (SMA): caused by mutations/deletions in the SMN1 gene encoding the survival motor neuron protein, which is a component of the snRNP assembly machinery required for spliceosome function. SMN deficiency impairs splicing globally but preferentially affects motor neurons, causing progressive muscle weakness and atrophy. Treatment: nusinersen (antisense oligonucleotide modifying splicing of SMN2, a backup gene) and onasemnogene abeparvovec (SMN1 gene therapy). Myotonic dystrophy: caused by CTG repeat expansion in the DMPK gene or CCTG expansion in CNBP gene → toxic expanded RNA sequesters splicing regulatory proteins (MBNL proteins) → widespread alternative splicing defects → multisystem disease including myotonia, cardiac conduction defects, cataracts, insulin resistance.